Top

Published in:

01-03-2010

Stepwise progression of pulmonary adenocarcinoma—clinical and molecular implications

Author: Masayuki Noguchi

Published in: Cancer and Metastasis Reviews | Issue 1/2010

Abstract

Stepwise progression of pulmonary adenocarcinoma is described from the viewpoint of both pathology and molecular biology. Pulmonary adenocarcinoma develops to invasive carcinoma through atypical adenomatous hyperplasia, adenocarcinoma in situ and minimally invasive adenocarcinoma. The Noguchi classification is well correlated with this sequential histological progression. On the other hand, in terms of molecular biology, p16 gene inactivation, EGFR mutation and KRAS mutation are early events, and tumors progress to invasive adenocarcinoma as a result of p53 mutation, loss of various chromosomes and other genetic abnormalities.

Travis, W. D., Lubin, J., Ries, L., & Devesa, S. (1996). United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer, 77, 2464–2470.CrossRefPubMed

Valaitis, J., Warren, S., & Gamble, D. (1981). Increasing incidence of adenocarcinoma of the lung. Cancer, 47, 1042–1046.CrossRefPubMed

Travis, W. D., Travis, L. B., & Devesa, S. S. (1995). Lung cancer. Cancer, 75, 191–202.CrossRefPubMed

Travis, W. D., Colby, T. V., Corrin, B., et al. (1999). WHO histological typing of lung and pleural tumors (3rd ed.). Geneva: World Health Organization.

Travis, W. D., Brambilla, E. B., Muller-Hermelink, H. K., & Harris, C. C. (2004). WHO pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARCPress.

Yatabe, Y., Mitsudomi, T., & Takahashi, T. (2002). TTF-1 expression in pulmonary adenocarcinomas. American Journal of Surgical Pathology, 26, 767–773.CrossRefPubMed

Nakayama, H., Noguchi, M., Tsuchiya, R., Kodama, T., & Shimosato, Y. (1990). Clonal growth of atypical adenomatous hyperplasia of the lung: cytofluorometric analysis of nuclear DNA content. Modern Pathology, 3, 314–320.PubMed

Anami, Y., Matsuno, Y., Yamada, T., et al. (1998). A case of double primary adenocarcinoma of the lung with multiple atypical adenomatous hyperplasia. Pathology International, 48, 634–640.CrossRefPubMed

Noguchi, M., Morikawa, A., Kawasaki, M., et al. (1995). Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer, 75, 2844–2852.CrossRefPubMed

10.

Nakamura, N., Iijima, T., Mase, K., et al. (2004). Phenotypic differences of proliferating fibroblasts in the stroma of lung adenocarcinoma and normal bronchus tissue. Cancer Science, 95, 226–232.CrossRefPubMed

11.

Minami, Y., Matsuno, Y., Iijima, T., et al. (2005). Prognostication of small-sized primary pulmonary adenocarcinomas by histopathological and karyometric analysis. Lung Cancer, 48, 339–348.CrossRefPubMed

12.

Suzuki, K., Yokose, T., Yoshida, J., et al. (2000). Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Annals of Thoracic Surgery, 69, 893–897.CrossRefPubMed

13.

Yokose, T., Suzuki, K., Nagai, K., Nishiwaki, Y., Sasaki, S., & Ochiai, A. (2000). Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter. Lung Cancer, 29, 179–188.CrossRefPubMed

14.

Sakurai, H., Maeshima, A., Watanabe, S., et al. (2004). Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. American Journal of Surgical Pathology, 28, 198–206.CrossRefPubMed

15.

Sakamoto, H., Shimizu, J., Horio, Y., et al. (2007). Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. Journal of Pathology, 212, 287–294.CrossRefPubMed

16.

Kobayashi, T., Tsuda, H., Noguchi, M., et al. (1990). Association of point mutation in c-Ki-ras oncogene in lung adenocarcinoma with particular reference to cytologic subtypes. Cancer, 66, 289–294.CrossRefPubMed

17.

Mok, T. S., Wu, Y. L., Yu, C. J., et al. (2009). Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small cell lung cancer. Journal of Clinical Oncology, 27, 5080–5087.CrossRefPubMed

18.

Paez, J. G., Janne, P. A., Lee, J. C., et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497–1500.CrossRefPubMed

19.

Lynch, T. J., Bell, D. W., Sordella, R., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. New England Journal of Medicine, 350, 2129–2139.CrossRefPubMed

20.

Takano, T., Ohe, Y., Sakamoto, H., et al. (2005). Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. Journal of Clinical Oncology, 23, 6829–6837.CrossRefPubMed

21.

Shigematsu, H., Lin, L., Takahashi, T., et al. (2005). Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. Journal of the National Cancer Institute, 97, 339–346.PubMedCrossRef

22.

Yatabe, Y., Takahashi, T., & Mitsudomi, T. (2008). Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Research, 68, 2106–2111.CrossRefPubMed

23.

Matsumoto, S., Iwakawa, R., Kohno, T., et al. (2006). Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma. International Journal of Cancer, 118, 2498–2504.CrossRef

24.

Tanaka, R., Wang, D., Morishita, Y., et al. (2005). Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma. Cancer, 103, 608–615.CrossRefPubMed

25.

Nakanishi, H., Matsumoto, S., Iwakawa, R., et al. (2009). Whole genome comparison of allelic imbalance between noninvasive and invasive small-sized lung adenocarcinomas. Cancer Research, 69, 1615–1623.CrossRefPubMed

26.

Sato, K., Ueda, Y., Shikata, H., & Katsuda, S. (2006). Bronchioloalveolar carcinoma of mixed mucinous and nonmucinous type: immunohistochemical studies and mutation analysis of the p53 gene. Pathology, Research and Practice, 202, 751–756.CrossRefPubMed

27.

Soda, M., Choi, Y. L., Enomoto, M., et al. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448, 561–566.CrossRefPubMed

28.

Inamura, K., Takeuchi, K., Togashi, Y., et al. (2008). EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. Journal of Thoracic Oncology, 3, 13–17.CrossRefPubMed

29.

Tanaka, R., Ishiyama, T., Uchihara, T., et al. (2006). Expression of the Bax inhibitor-1 gene in pulmonary adenocarcinoma. Cancer, 106, 648–653.CrossRefPubMed

Title: Stepwise progression of pulmonary adenocarcinoma—clinical and molecular implications
Author: Masayuki Noguchi
Publication date: 01-03-2010
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 1/2010
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-010-9210-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

DNA methylation markers in colorectal cancer

Lung cancer: From single-gene methylation to methylome profiling

Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy

Cetuximab in combination therapy: from bench to clinic

EGFR mutations and the terminal respiratory unit

Natural history of bronchial preinvasive lesions

Keynote webinar | Spotlight on antibody–drug conjugates in cancer